Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Sep 20;6(10):e1156.
doi: 10.1097/CCE.0000000000001156. eCollection 2024 Oct.

The Association Between Vasopressin and Adverse Kidney Outcomes in Children and Young Adults Requiring Vasopressors on Continuous Renal Replacement Therapy

Collaborators, Affiliations
Multicenter Study

The Association Between Vasopressin and Adverse Kidney Outcomes in Children and Young Adults Requiring Vasopressors on Continuous Renal Replacement Therapy

Denise C Hasson et al. Crit Care Explor. .

Abstract

Objectives: Continuous renal replacement therapy (CRRT) and shock are both associated with high morbidity and mortality in the ICU. Adult data suggest renoprotective effects of vasopressin vs. catecholamines (norepinephrine and epinephrine). We aimed to determine whether vasopressin use during CRRT was associated with improved kidney outcomes in children and young adults.

Design: Secondary analysis of Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK), a multicenter, retrospective cohort study.

Setting: Neonatal, cardiac, PICUs at 34 centers internationally from January 1, 2015, to December 31, 2021.

Patients/subjects: Patients younger than 25 years receiving CRRT for acute kidney injury and/or fluid overload and requiring vasopressors. Patients receiving vasopressin were compared with patients receiving only norepinephrine/epinephrine. The impact of timing of vasopressin relative to CRRT start was assessed by categorizing patients as: early (on or before day 0), intermediate (days 1-2), and late (days 3-7).

Interventions: None.

Measurements and main results: Of 1016 patients, 665 (65%) required vasopressors in the first week of CRRT. Of 665, 248 (37%) received vasopressin, 473 (71%) experienced Major Adverse Kidney Events at 90 days (MAKE-90) (death, renal replacement therapy dependence, and/or > 125% increase in serum creatinine from baseline 90 days from CRRT initiation), and 195 (29%) liberated from CRRT on the first attempt within 28 days. Receipt of vasopressin was associated with higher odds of MAKE-90 (adjusted odds ratio [aOR], 1.80; 95% CI, 1.20-2.71; p = 0.005) but not liberation success. In the vasopressin group, intermediate/late initiation was associated with higher odds of MAKE-90 (aOR, 2.67; 95% CI, 1.17-6.11; p = 0.02) compared with early initiation.

Conclusions: Nearly two-thirds of children and young adults receiving CRRT required vasopressors, including over one-third who received vasopressin. Receipt of vasopressin was associated with more MAKE-90, although earlier initiation in those who received it appears beneficial. Prospective studies are needed to understand the appropriate timing, dose, and subpopulation for use of vasopressin.

Keywords: Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease; acute kidney injury; dialysis; vasoactives; vasopressor.

PubMed Disclaimer

Conflict of interest statement

Dr. Stanski received funding from the National Institute of General Medical Sciences (K23GM151444-01). Dr. Gist is a consultant for BioPorto Diagnostics and Potrero Medical; she received funding from the Gerber Foundation. Dr. Stenson received funding from the National Institute of Child Health and Development (K12HD047349). Dr. Ollberding serves as a consultant for SeaStar Medical. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Figures

Figure 1.
Figure 1.
Consolidated Standards of Reporting Trials flow diagram. CRRT = continuous renal replacement therapy, VA = vasopressin, WE-ROCK = Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease.
Figure 2.
Figure 2.
Median daily percent change in Vasoactive-Inotropic Score (VIS) by timing of vasopressin initiation (early, intermediate, or late) in all patients receiving vasopressin (VA group). CRRT = continuous renal replacement therapy.

References

    1. Kaddourah A, Basu RK, Bagshaw SM, et al. ; AWARE Investigators: Epidemiology of acute kidney injury in critically ill children and young adults. N Engl J Med 2017; 376:11–20 - PMC - PubMed
    1. Riley AA, Watson M, Smith C, et al. : Pediatric continuous renal replacement therapy: Have practice changes changed outcomes? A large single-center ten-year retrospective evaluation. BMC Nephrol 2018; 19:268. - PMC - PubMed
    1. Sutherland SM, Zappitelli M, Alexander SR, et al. : Fluid overload and mortality in children receiving continuous renal replacement therapy: The prospective pediatric continuous renal replacement therapy registry. Am J Kidney Dis 2010; 55:316–325 - PubMed
    1. Goldstein SL, Currier H, Graf Cd, et al. : Outcome in children receiving continuous venovenous hemofiltration. Pediatrics 2001; 107:1309–1312 - PubMed
    1. Basu RK, Zappitelli M, Brunner L, et al. : Derivation and validation of the renal angina index to improve the prediction of acute kidney injury in critically ill children. Kidney Int 2014; 85:659–667 - PMC - PubMed

Publication types

LinkOut - more resources